May 03, 2017 - 02:00 pm - 00:00 am
Bad Homburg, Germany
Conference Call Q1 2017, Fresenius
Live webcast
Fresenius SE & Co. KGaA (“Fresenius”) will focus its reporting on financial statements in accordance with International Financial Reporting Standards (IFRS) starting with the 2017 fiscal year on January 1, 2017. The company will then no longer provide U.S. GAAP financial information.
Fresenius, as a publicly traded company based in a European Union member country, is required to prepare and publish its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) pursuant to Section 315a of the German Commercial Code (HGB).
In addition to this compulsory IFRS accounting, Fresenius also publishes consolidated financial statements in accordance with U.S. GAAP. This has provided comparability with the Group’s largest subsidiary, Fresenius Medical Care, which was required to report in accordance with U.S. GAAP under a so-called Pooling Agreement. However, Fresenius Medical Care’s 2016 Annual General Meeting has lifted this obligation.
In the interest of harmonizing the management and accounting of the Fresenius Group and all of its business segments, the Fresenius Group and all of its business segments will report solely in accordance with IFRS starting with the 2017 fiscal year on January 1, 2017.
For the 2016 fiscal year, Fresenius will as in past years provide both U.S. GAAP and IFRS consolidated financial statements.
No significant differences between IFRS and U.S. GAAP financial statements
Past reporting showed only limited differences between the consolidated U.S. GAAP and IFRS accounts of Fresenius SE & Co. KGaA. Historic IFRS figures for the Fresenius Group and its individual business segments are provided on our Investor Relations website.
No effect on the ADR program
The discontinuation of U.S. GAAP reporting will not affect the sponsored Level 1 American Depositary Receipt (ADR) program of Fresenius SE & Co. KGaA in the United States. The ADRs will continue to trade under the FSNUY ticker on the over-the-counter OTCQX International Premier market.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
November 28, 2016
Boca Raton, USA
Bank of America Merrill Lynch – Leveraged Finance Conference 2016
Fresenius Helios has laid the foundation stone for a new main building at HELIOS Hospital Dr. Horst Schmidt Kliniken in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with 96,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, more than 900 beds, and a design that significantly reduces distances and waiting times for patients. HELIOS is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2020.
Fresenius Helios has laid the foundation stone for a new main building at HELIOS Hospital Dr. Horst Schmidt Kliniken in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with 96,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, more than 900 beds, and a design that significantly reduces distances and waiting times for patients. HELIOS is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2020.
February 22, 2017 - 10:00 am - 00:00 am
Bad Homburg, Germany
Press Conference Full Year Results 2016, Fresenius and Fresenius Medical Care
Live webcast
Bivalirudin for Injection, a direct thrombin inhibitor, expands the company's anticoagulant portfolio.